 Linezolid 's spectrum of activity against Gram @-@ positive bacteria is similar to that of the glycopeptide antibiotic vancomycin , which has long been the standard for treatment of MRSA infections , and the two drugs are often compared . Other comparable antibiotics include teicoplanin ( trade name Targocid , a glycopeptide like vancomycin ) , quinupristin / dalfopristin ( Synercid , a combination of two streptogramins , not active against E. faecalis ) , and daptomycin ( Cubicin , a lipopeptide ) , and some agents still being developed , such as ceftobiprole , dalbavancin , and telavancin . Linezolid is the only one that can be taken by mouth . In the future , oritavancin and iclaprim may be useful oral alternatives to linezolid — both are in the early stages of clinical development . 
